HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.

Résumé : New therapeutic options are needed for patients with psoriasis. Tofacitinib, an oral Janus kinase inhibitor, is being investigated as a treatment for moderate-to-severe chronic plaque psoriasis. In this study, we aimed to compare two tofacitinib doses with high-dose etanercept or placebo in this patient population.
Complete list of metadata

https://hal.univ-brest.fr/hal-01558410
Contributor : Ghislaine Calvez Connect in order to contact the contributor
Submitted on : Friday, July 7, 2017 - 4:05:16 PM
Last modification on : Thursday, January 20, 2022 - 3:39:58 AM

Identifiers

  • HAL Id : hal-01558410, version 1
  • PUBMED : 26051365

Citation

Hervé Bachelez, Peter C M van de Kerkhof, Robert Strohal, Alexey Kubanov, Fernando Valenzuela, et al.. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.. The Lancet, Elsevier, 2015, 386 (9993), pp.552-61. ⟨hal-01558410⟩

Share

Metrics

Record views

36